Active	Status	Sponsor type	Region	Phase	Filter
9 Active 6 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Mi Kyeong
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
NCT06100289: A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease	Recruiting	3	70	Europe, Japan, US, RoW	Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002, Vedolizumab SC, MLN0002SC	Takeda	Ulcerative Colitis, Crohn's Disease	06/27	06/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Recruiting	3	90	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Crohn's Disease	07/27	10/27
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment	Recruiting	2	38	RoW	Avelumab and Gemcitabine	Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp.	Leiomyosarcoma Metastatic	12/21	12/22
ERTEMIS, NCT05540587: Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis	Recruiting	2	240	RoW	Edoxaban, Warfarin	Sung-Hwan Kim, Daiichi Sankyo Korea Co., Ltd.	Mitral Valve Stenosis, Atrial Fibrillation, Stroke, Systemic Embolism	05/24	05/26
KOBI, NCT05428137: Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals	Recruiting	N/A	180	RoW	Probiotic, Postbiotic, Placebo	The Archer-Daniels-Midland Company	Obesity, Abdominal Obesity	12/24	12/24
NCT06049914: Combined Exercise and Nutrition Intervention for Possible Sarcopenia Among Older Adults in Primary Care	Recruiting	N/A	94	RoW	Experimental group	Kyunghee University Medical Center	Sarcopenia	12/24	12/24
Vidal, Daniel Ramon
KOBI, NCT05428137: Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals	Recruiting	N/A	180	RoW	Probiotic, Postbiotic, Placebo	The Archer-Daniels-Midland Company	Obesity, Abdominal Obesity	12/24	12/24
Sang-wook, Song
KOBI, NCT05428137: Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals	Recruiting	N/A	180	RoW	Probiotic, Postbiotic, Placebo	The Archer-Daniels-Midland Company	Obesity, Abdominal Obesity	12/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Mi Kyeong
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
NCT06100289: A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease	Recruiting	3	70	Europe, Japan, US, RoW	Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002, Vedolizumab SC, MLN0002SC	Takeda	Ulcerative Colitis, Crohn's Disease	06/27	06/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Recruiting	3	90	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Crohn's Disease	07/27	10/27
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment	Recruiting	2	38	RoW	Avelumab and Gemcitabine	Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp.	Leiomyosarcoma Metastatic	12/21	12/22
ERTEMIS, NCT05540587: Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis	Recruiting	2	240	RoW	Edoxaban, Warfarin	Sung-Hwan Kim, Daiichi Sankyo Korea Co., Ltd.	Mitral Valve Stenosis, Atrial Fibrillation, Stroke, Systemic Embolism	05/24	05/26
KOBI, NCT05428137: Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals	Recruiting	N/A	180	RoW	Probiotic, Postbiotic, Placebo	The Archer-Daniels-Midland Company	Obesity, Abdominal Obesity	12/24	12/24
NCT06049914: Combined Exercise and Nutrition Intervention for Possible Sarcopenia Among Older Adults in Primary Care	Recruiting	N/A	94	RoW	Experimental group	Kyunghee University Medical Center	Sarcopenia	12/24	12/24
Vidal, Daniel Ramon
KOBI, NCT05428137: Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals	Recruiting	N/A	180	RoW	Probiotic, Postbiotic, Placebo	The Archer-Daniels-Midland Company	Obesity, Abdominal Obesity	12/24	12/24
Sang-wook, Song
KOBI, NCT05428137: Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals	Recruiting	N/A	180	RoW	Probiotic, Postbiotic, Placebo	The Archer-Daniels-Midland Company	Obesity, Abdominal Obesity	12/24	12/24